In the era of personalized medicine and targeted therapies for the management of patients
with cancer, ultrasensitive detection methods for tumor genotyping, such as next-generation …

Few data are available that have compared outcomes with different EGFR tyrosine kinase
inhibitors (TKIs) specifically in Asian patients with EGFR mutation-positive non-small-cell …

The treatment of patients with advanced non-small-cell lung cancer (NSCLC) in recent years
has been increasingly guided by biomarker testing. Testing has centered on driver genetic …

Since their discovery, relevant efforts have been made to optimize the detection approaches
to EGFR mutations as well as the clinical management of EGFR-mutated NSCLC. The …

Activating mutations in EGFR predict benefit from tyrosine kinase inhibitor therapy for
patients with advanced non-small cell lung cancer. Directing patients to appropriate therapy …

Simple Summary In advanced non-small cell lung cancer (NSCLC) patients, tumor tissue
biopsy represents the gold standard for molecular analysis procedures. However, to achieve …

Sensitive detection of resistance mutation T790 M is of great significance for early diagnosis
and prognostic monitoring of non-small-cell lung cancer (NSCLC). In this paper, we showed …

Purpose Epidermal growth factor receptor (EGFR) T790M mutations have been detected in
the second or third rebiopsy, even if the T790M mutation was not identified in the first …

Background This is a pilot proof-of-concept study to evaluate the utility of a custom 15-gene
circulating tumor DNA (ctDNA) panel as a potential companion molecular next-generation …

Purpose This single-center, open-label, single-arm, phase II clinical trial aimed to examine
the efficacy and safety of the first-generation EGFR-TKIs combined with chemotherapy …